pabal 100 mikrogramm/ml injektionslösung
ferring gmbh (3076475) - carbetocin - injektionslösung - teil 1 - injektionslösung; carbetocin (24120) 0,1 milligramm
pabal 100 µg/ml injektionslösung
ferring - carbetocin - injektionslösung - 100 µg/ml - carbetocin 100 µg/ml - carbetocin
pabal injektionslösung
ferring ag - carbetocinum - injektionslösung - carbetocinum 100 µg, acidum succinicum, mannitolum, methioninum, natrii hydroxidum q.s. ad ph, aqua ad iniectabile q.s., ad solutionem pro 1 ml corresp. natrium 0.386 mg. - prävention uteriner blutungen aufgrund einer postpartalen uterusatonie - biotechnologika
pabal 100 mikrogramm/ml - injektionslösung
ferring arzneimittel ges.m.b.h - carbetocin - carbetocin
pabal 100 µg/ml injektionslösung
eurimpharm arzneimittel gmbh - carbetocin - injektionslösung - carbetocin 0.1mg
pabalate sf dragees
diapharm gmbh & co. kg - 2-hydroxybenzoesäure-kaliumsalz - dragees - 2-hydroxybenzoesäure-kaliumsalz 300.mg
pabalate dragees
diapharm gmbh & co. kg - ascorbinsäure, natriumsalicylat, 4-aminobenzoesäure-natriumsalz - dragees - ascorbinsäure 50.mg; natriumsalicylat 300.mg; 4-aminobenzoesäure-natriumsalz 300.mg
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotische mittel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
rivaroxaban sandoz 10 mg filmtablette
sandoz - rivaroxaban - filmtablette - 10 mg - rivaroxaban 10 mg - rivaroxaban
rivaroxaban sandoz 15 mg filmtablette
sandoz - rivaroxaban - filmtablette - 15 mg - rivaroxaban 15 mg - rivaroxaban